RecruitingNot Applicable

Colon Cancer Liquid Biopsy Investigation of Methylation-based Biomarkers Evaluation Using Delta-HLD (CLIMBED)

Argentina3,200 participantsStarted 2024-04-04

Plain-language summary

CLIMBED (Colon cancer Liquid biopsy Investigation of Methylation-based Biomarkers Evaluation using Delta-HLD) is a non-randomized, observational, cross-sectional clinical validation study designed to assess the performance of Delta-HLD, Epiliquid's proprietary liquid biopsy technology, for colorectal cancer (CRC) detection. The study will evaluate the test performance in an average-risk population for CRC undergoing screening colonoscopy, which will serve as the gold standard reference.

Who can participate

Age range45 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Men and women aged 45-75 years * Indication of colorectal cancer screening colonoscopy by treating physician Exclusion Criteria: * First-degree family history of CRC * Inflammatory bowel disease (ulcerative colitis, Crohn's disease) * Other malignancies within 5 years * Known hereditary CRC syndromes (Lynch, FAP) * Major trauma, surgery, transfusion in past 30 days * Current participation in an interventional clinical trial

What they're measuring

Sensitivity of colorectal cancer detection

Timeframe: 18 months

Specificity of advanced neoplasia detection

Timeframe: 36 months

Trial details

NCT IDNCT07168876

SponsorEpiliquid Holding, Inc

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2025-12

Contact for this trial

Dr. Victoria Bocanegra, MD, PhD.

+5492616603254 victoria.bocanegra@epiliquid.com

View on ClinicalTrials.gov More Colorectal Cancer (CRC) trials